World Library  
Flag as Inappropriate
Email this Article

Allylestrenol

Article Id: WHEBN0026781350
Reproduction Date:

Title: Allylestrenol  
Author: World Heritage Encyclopedia
Language: English
Subject: Progestogens, Progestogen only contraception, Cyproterone acetate, Algestone acetophenide, Dimethisterone
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Allylestrenol

Allylestrenol
Systematic (IUPAC) name
(17β)-17-(prop-2-en-1-yl)estr-4-en-17-ol
Clinical data
Pregnancy cat.
  • Used in threatened miscarriage and RPL
Legal status
?
Identifiers
CAS number  YesY
ATC code G03
PubChem
DrugBank
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEMBL  N
Synonyms 17α-Allylestr-4-en-17β-ol
Chemical data
Formula C21H32O 
Mol. mass 300.48 g/mol
 N   

Allylestrenol (BAN/INN), also known as allyloestrenol and allyl estrenol, is a synthetic progestogen used to prevent threatened miscarriage, recurrent pregnancy loss and premature labor.[1][2] In men, it has also been studied as a treatment for benign prostatic hyperplasia, with encouraging results.[3][4]

Allylestrenol is sold under several trade names, including Gestin, Turinal,Gestrenol, Gestanin, Gestanol or Gestanon, Maintaine, Orageston, and Profar. It is currently not marketed in the United States, United Kingdom, or Canada, but as of 2011, is extensively used in Bangladesh,Japan, Russia, India, and much of Southeast Asia.[1]

References

  1. ^ a b Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2082.  
  2. ^ Cortés-Prieto J, Bosch AO, Rocha JA (1980). "Allylestrenol: three years of experience with Gestanon in threatened abortion and premature labor". Clinical Therapeutics 3 (3): 200–8.  
  3. ^ Fukuoka H, Ishibashi Y, Shiba T, Tuchiya F, Sakanishi S (July 1993). "[Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese) 39 (7): 679–83.  
  4. ^ Noguchi K, Takeda M, Hosaka M, Kubota Y (May 2002). "[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese) 48 (5): 269–73.  

External links

  • "AUA 2007 - Prostate Cancer Basic Research (II)" - Uro Today


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.